Lv7
3710 积分 2023-04-23 加入
The U.S. Food and Drug Administration’s Perspective on Chimeric Antigen Receptor T-Cell Therapies for Autoimmune and Rheumatic Conditions
26天前
已完结
POS1307 SUSTAINED EFFICACY OF POZDEUTINURAD (AR882): LONG-TERM TREATMENT EFFECT OF A NOVEL AND SELECTIVE URAT1 INHIBITOR IN PATIENTS WITH CHRONIC GOUTY ARTHRITIS
1个月前
已关闭
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials
3个月前
已完结
New Treatments in Atopic Dermatitis Update
4个月前
已完结
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
5个月前
已完结
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
5个月前
已完结
Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial
5个月前
已完结
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
5个月前
已完结
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation
5个月前
已完结
Dupilumab Efficacy in Type 2 Inflammatory Asthma: Liberty Asthma QUEST Study
5个月前
已关闭
皖公网安备34019202002308
